BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-657@pharmaconomics
DTSTAMP:20260707T014317Z
DTSTART;VALUE=DATE:20260101
DTEND;VALUE=DATE:20260102
SUMMARY:IBRX Approval — ANKTIVA
DESCRIPTION:A final FDA approval decision on ANKTIVA for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) is expected Jan 1\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000018/ibrx-20262188xkexhibit991.htm\n\nTrack it: https://pharmaconomics.com/e/657
URL:https://pharmaconomics.com/e/657
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IBRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR